Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

• Status: Completed
• Trial end date: 1969-12-31

Summary

The aim of this post-marketing surveillance is to obtain further information about the tolerability of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Fenoterol; Fenoterol, ipratropium drug combination; Ipratropium